Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- MannKind Corporation Q3 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. (Operator's Instructions). Our first question today comes from Tom Shrader of Rodman. Thomas Shrader - Rodman & Renshaw Good morning. Alfred Mann Good morning, Tom. Thomas Shrader - Rodman & Renshaw Hope you guys are enjoying the calm before the...
- Earnings calls 2008-11-05
Additional Resources
- Sanofi's Lantus Cancer Scare Shows How Enormous Power Lies With Few Experts
- The cancer scare over Sanofi-Aventis' Lantus shows just how much power over a company's drug sales -- and its stock -- are now concentrated in the hands of a tiny number of experts. Sanofi CEO Chris Viehbacher came out of his corner swinging Monday, saying an article in Study of...
- Blog posts 2009-06-29
- Sanofi-Aventis Stock Recovering After Lantus Leak
- Mike Huckman submits: Shares of Sanofi-Aventis SNY are getting a little investor injection on the back of the emergency release of the Lantus diabetic insulin studies late last Friday. The stock had fallen about 10 percent late last week on rumors that reports were about to be published in...
- External links 2009-06-29
- UPDATED: Sanofi's Lantus Cancer Scare Triggered by Doc Backed by Amylin and Lilly
- The editors of medical journal backed off from a study they published suggesting Sanofi-Aventis' diabetes drug Lantus was linked to cancer. At the same time, it emerged that the doctor who warned of an "earthquake" on Lantus has done work endorsed or sponsored by Amylin and Eli Lilly, marketers of...
- Blog posts 2009-07-01
- Cynicism Winning Debate Over Sanofi's Lantus and Cancer
- In the flap over whether Sanofi-Aventis' Lantus diabetes drug has an association with cancer, cynicism seems to be winning. Sanofi's stock see graph seems not to have recovered from reports that Lantus was linked to cancer, even though Sanofi obtained an approval for a new heart drug, Multaq. Meanwhile, Sanofi's...
- Blog posts 2009-07-07
- Medtronic Insulin Pumps Help Pediatric Patients with Type 1 Diabetes Achieve Significantly Better Blood Sugar Control Compared to Lantus
- NORTHRIDGE, Calif. -- First randomized, prospective study directly comparing insulin pumps with LantusR therapy in pediatric patients identifies pump therapy as a more optimal treatment for blood sugar control
- Research articles 2004-07-02
- Flamel Technologies Announces Positive Results of a Phase I Trial of FT-105 Basal Insulin versus Lantus®
- LYON, France -- Flamel Technologies (NASDAQ:FLML) today announced positive preliminary Phase I data from a trial comparing the safety, tolerability, and long-acting activity of FT-105 versus Lantus[R], an approved basal insulin. FT-105 is a long-acting recombinant insulin formulation that uses a new microparticulate adaptation of Flamel's proprietary Medusa[R] nanoparticle delivery...
- Research articles 2007-10-18
- Media Alert: Diabetes Experts Available To Discuss Latest Insulin At American Diabetes Association Meeting
- WHAT:An opportunity to meet with key investigators and diabetes thought leaders, at the American Diabetes Association annual meeting, to discuss LantusR (insulin glargine [rDNA origin] injection), the first and only insulin analog that provides 24-hour coverage with just one shot for the treatment of diabetes, which is now available by...
- Research articles 1970-01-01
- Sanofi-Aventis Reaffirms Commitment to China Public Health with New Facility
- ChinaBio Today submits: Sanofi-Aventis (NYSE: SNY) will invest 600 million RMB ($90 million) to expand its Beijing manufacturing facility to produce the company’s insulin drug, Lantus. Lantus is a pre-filled injection, delivered via the SoloSTAR pen device, which provides once-daily insulin to people with type 1 and type 2...
- External links 2009-04-21
- INSULIN GLARGINE.(new insulin medication launched by Aventis)(Brief Article)
- Aventis has launched Lantus (insulin glargine [rDNA origin] injection), the first insulin analog that provides 24-hour glucose lowering activity with just one shot, in the US. ... Aventis has launched Lantus (insulin glargine [rDNA origin] injection), the first insulin analog that provides 24-hour glucose...
- Research articles 2001-05-28
- Account action. (Hot Spots).(advertising account news briefs)(Brief Article)
- AVENTIS PHARMACEUTICALS has awarded its $100 million account for its diabetes drug Lantus to HAVAS'S EURO RSCG. Last month, Aventis trimmed the finalists to Euro RSCG, HEALTHY GREY unit of Grey Global and WPP GROUP'S Y&R ADVERTISING. Each age AVENTIS PHARMACEUTICALS has awarded its...
- Research articles 2003-01-20
- Sanofi Lifts Forecast on Swine Flu Vaccine
- By Caroline JacobsPARIS (Reuters) - Sanofi-Aventis SASY raised its outlook for 2009 thanks to sales of swine flu vaccine and posted earnings per share growth that beat forecasts as competition from generics was offset by revenue growth for other drugs.Sanofi expected H1N1 vaccines to add about $500 million to its...
- News items 2009-10-30
- Human Studies show Flamel Technologies' Medusa Protein Delivery System BASULIN Challenges Lantus for the 24-hour Controlled Release of Insulin
- Business Editors/Health/Medical Writers
- Research articles 2003-03-24
- Aventis tightens PR roster
- AVENTIS has hired BursonMarsteller to handle PR for its diabetes drug Lantus as it begins consolidating its global PR agency roster under the direction of new global product communications head David Owens.
- Research articles 2003-04-01
- Aventis launches Lantus.
- Brazil, Aug 20, 2003 (Gazeta Mercantil/SABI via COMTEX) Brazil, Aug 20, 2003 (Gazeta Mercantil/SABI via COMTEX)
- Research articles 2003-08-20
- Judge thows out Sanofi's case against rival's claim
- A JUDGE THREW out SanofiAventis' case against claims for Novo Nordisk's insulin Levemir. Sanofi-Aventis, which markets competitor Lantus, had charged that Levemir does not last for 24 hours, as claimed in Levemir prelaunch and launch promotions, and sought a preliminary injunction in the New Jersey US District Court. The judge...
- Research articles 2006-08-01
- Novo Nordisk to grow diabetes reach
- NOVO NORDISK has announced a bid to expand its 40% share of the worldwide diabetes market via its sales reach. The Danish company already sells to 60% of U.S. doctors, but will now call on smaller medical practices to reach a new goal of 80%, according to a report published...
- Research articles 2006-01-01
- Oral-lyn vs. Afresa: How Generex Will Beat Mannkind
- R.J Steffens submits: As biotech companies and large pharma embark on paths to usher in more effective diabetes drugs to market, one of the more significant concerns regarding diabetes related drug development is safety. The FDA has increasingly issued new alerts from previously approved drugs such as GlaxoSmithKline's GSK Avandia,...
- External links 2009-11-19
- << Previous
- page 1 of 1
- Next >>
